Cholinergic Antagonists — MCQs
Non-depolarizing neuromuscular blocker is characterized by
All of the following drugs are used for the treatment of urinary incontinence except:
Which medication is the primary treatment for muscarinic effects in acute organophosphate poisoning?
What is the mechanism of action of Curare drugs as muscle relaxants?
What is a contraindication of antimuscarinic drugs?
A patient presented to the emergency department with an overdose of a drug, exhibiting increased salivation and increased bronchial secretions. On examination, the blood pressure was 88/60 mmHg, and the RBC cholinesterase level was reduced to 50% of normal. What should be the treatment for this individual?
A 68-year-old with depression and chronic pain is on amitriptyline. What side effect may arise if given oxybutynin for overactive bladder?
Mechanism of action of d-tubocurarine is:
Mechanism of action of curare-like drugs?
A patient with diabetes and COPD developed postoperative urinary retention. Which of the following drugs can be used for short term treatment to relieve the symptoms of this person?
Cholinergic Antagonists Indian Medical PG Practice Questions and MCQs
Question 1: Non-depolarizing neuromuscular blocker is characterized by
- A. Non competitive neuromuscular blocker
- B. Reversed by neostigmine (Correct Answer)
- C. Induces fasciculations
- D. Persistent stimulator of nicotinic cholinergic receptors
Explanation: ***Reversed by neostigmine*** - **Non-depolarizing neuromuscular blockers** are **competitive antagonists** at the **nicotinic acetylcholine receptors** at the neuromuscular junction. - **Neostigmine** is an **acetylcholinesterase inhibitor** that increases the concentration of acetylcholine in the synaptic cleft, thereby overcoming the competitive blockade. *Non competitive neuromuscular blocker* - Non-depolarizing neuromuscular blockers are, by definition, **competitive antagonists** at the **nicotinic acetylcholine receptors**. - A non-competitive blocker would bind to a different site on the receptor or an allosteric site to produce its effect. *Induces fasciculations* - **Fasciculations** (visible muscle twitching) are characteristic of **depolarizing neuromuscular blockers** like **succinylcholine**, as they initially activate the receptors before causing prolonged depolarization and paralysis. - Non-depolarizing blockers do not typically cause fasciculations because they prevent acetylcholine from binding and activating the receptors. *Persistent stimulator of nicotinic cholinergic receptors* - This describes the mechanism of action of **depolarizing neuromuscular blockers** like **succinylcholine**, which persistently activate the receptor, leading to initial fasciculations followed by sustained depolarization and paralysis. - **Non-depolarizing blockers** act as **antagonists**, preventing activation of the receptors.
Question 2: All of the following drugs are used for the treatment of urinary incontinence except:
- A. Ipratropium (Correct Answer)
- B. Oxybutynin
- C. Tolterodine
- D. Darifenacin
Explanation: ***Ipratropium*** - **Ipratropium** is a short-acting muscarinic antagonist primarily used as a **bronchodilator** in obstructive lung diseases. - While it has anticholinergic properties, it is not typically used for **urinary incontinence** due to its limited systemic absorption and short duration of action, making it less effective for bladder control compared to other agents. *Oxybutynin* - **Oxybutynin** is a commonly prescribed **muscarinic antagonist** that acts by relaxing the bladder detrusor muscle, increasing bladder capacity and reducing involuntary contractions. - It is effective in treating **overactive bladder** and urge incontinence. *Tolterodine* - **Tolterodine** is a **muscarinic receptor antagonist** that specifically targets M2 and M3 receptors in the bladder, reducing bladder hyperreactivity. - It is used for the symptomatic treatment of **urge incontinence** and overactive bladder. *Darifenacin* - **Darifenacin** is a highly M3-selective muscarinic receptor antagonist, which means it primarily blocks the M3 receptors responsible for **detrusor muscle contraction**. - Its selectivity helps minimize side effects common to less selective anticholinergics and is used for the treatment of **overactive bladder** with symptoms of urgency, frequency, and urge incontinence.
Question 3: Which medication is the primary treatment for muscarinic effects in acute organophosphate poisoning?
- A. Atropine (Correct Answer)
- B. Tubocurarine
- C. Neostigmine
- D. Pralidoxime
Explanation: ***Atropine*** - **Atropine** is a **muscarinic receptor antagonist** that directly blocks the effects of excessive acetylcholine at muscarinic sites, thereby reversing symptoms like bradycardia, bronchospasm, and excessive secretions seen in organophosphate poisoning. - It is the **primary agent** used to manage the muscarinic symptoms and is titrated until bronchorrhea and bronchospasm resolve. *Neostigmine* - **Neostigmine** is an **acetylcholinesterase inhibitor**, which would worsen the condition by increasing acetylcholine levels further. - It is used in conditions like **myasthenia gravis** to improve muscle strength, not in organophosphate poisoning. *Tubocurarine* - **Tubocurarine** is a **nicotinic receptor antagonist**, specifically a competitive neuromuscular blocker. - While organophosphate poisoning can affect nicotinic receptors, tubocurarine is not the primary treatment for muscarinic effects and could worsen respiratory depression in this context. *Pralidoxime* - **Pralidoxime** (2-PAM) is an **acetylcholinesterase reactivator** that can regenerate the enzyme, thereby reversing both muscarinic and nicotinic effects. - While crucial for reversing nicotinic effects and preventing 'aging' of the enzyme, it is **not the primary treatment for acute muscarinic crisis**; atropine is.
Question 4: What is the mechanism of action of Curare drugs as muscle relaxants?
- A. Persistently depolarizing at Neuromuscular junction
- B. Act competitively on Ach receptors blocking post-synaptically (Correct Answer)
- C. Repetitive stimulation of Ach receptors on muscle end plate
- D. Inhibiting the calcium channel on presynaptic membrane
Explanation: ***Act competitively on Ach receptors blocking post-synaptically*** - Curare-like drugs are **non-depolarizing neuromuscular blockers** that exhibit their effects by **competitively binding** to **nicotinic acetylcholine receptors** on the **postsynaptic membrane** of the neuromuscular junction. - This competitive binding prevents acetylcholine (ACh) from binding to its receptors, thereby inhibiting the generation of an **end-plate potential** and subsequent **muscle contraction**. *Persistently depolarizing at Neuromuscular junction* - This mechanism is characteristic of **depolarizing neuromuscular blockers** like **succinylcholine**, which first cause muscle fasciculations followed by paralysis due to persistent receptor activation and inactivation of voltage-gated sodium channels. - Curare-like drugs do not cause persistent depolarization; instead, they prevent depolarization by blocking ACh access to receptors. *Repetitive stimulation of Ach receptors on muscle end plate* - **Repetitive stimulation** of acetylcholine (ACh) receptors by ACh itself leads to muscle contraction, not relaxation. - Curare-like drugs *block* the ability of ACh to stimulate these receptors, thus preventing contraction. *Inhibiting the calcium channel on presynaptic membrane* - Inhibiting presynaptic calcium channels would reduce the **release of acetylcholine** from the presynaptic terminal. - While this would lead to muscle relaxation, it is not the primary mechanism of action for **curare-like drugs**, which act directly on the postsynaptic receptors.
Question 5: What is a contraindication of antimuscarinic drugs?
- A. Peptic ulcer
- B. Glaucoma (Correct Answer)
- C. Asthma
- D. Urinary incontinence
Explanation: ***Correct: Glaucoma*** - Antimuscarinic drugs cause **mydriasis (pupil dilation)** and **cycloplegia**, which increases intraocular pressure, especially in individuals with **narrow-angle glaucoma**. - In narrow-angle glaucoma, pupil dilation causes the peripheral iris to bunch up and block the trabecular meshwork, obstructing aqueous humor outflow. - This can precipitate an **acute angle-closure glaucoma attack**, a medical emergency, making glaucoma an **absolute contraindication** to antimuscarinic drugs. - This is one of the most important contraindications to remember for all anticholinergic medications. *Incorrect: Peptic ulcer* - Antimuscarinic drugs were **historically used to treat** peptic ulcer disease by reducing gastric acid secretion and gastrointestinal motility. - While they are no longer first-line therapy (replaced by proton pump inhibitors and H2 blockers), peptic ulcer is **not a contraindication**. - The main reason they fell out of favor was due to side effects and less efficacy compared to modern alternatives, not because they worsen the condition. *Incorrect: Asthma* - Some antimuscarinics (e.g., **ipratropium, tiotropium**) are actually used as **bronchodilators** in asthma and COPD management. - They work by blocking muscarinic receptors in airway smooth muscle, causing bronchodilation. - Therefore, asthma is a **treatment indication**, not a contraindication. *Incorrect: Urinary incontinence* - Antimuscarinic drugs are the **primary pharmacological treatment** for overactive bladder and urge incontinence. - They work by blocking M3 muscarinic receptors in the detrusor muscle, reducing bladder contractions. - Common drugs include oxybutynin, tolterodine, and solifenacin. - Urinary incontinence is a **treatment indication**, not a contraindication.
Question 6: A patient presented to the emergency department with an overdose of a drug, exhibiting increased salivation and increased bronchial secretions. On examination, the blood pressure was 88/60 mmHg, and the RBC cholinesterase level was reduced to 50% of normal. What should be the treatment for this individual?
- A. Atropine (Correct Answer)
- B. Physostigmine
- C. Flumazenil
- D. Neostigmine
Explanation: ***Atropine*** - The patient exhibits symptoms of **cholinergic crisis** (increased salivation, bronchial secretions, hypotension) and reduced RBC esterase, strongly indicative of **organophosphate poisoning**. - **Atropine** is the primary antidote, as it competitively blocks muscarinic acetylcholine receptors, reversing the parasympathetic effects. *Neostigmine* - **Neostigmine** is an **acetylcholinesterase inhibitor**, meaning it would worsen the cholinergic crisis by increasing acetylcholine levels further. - It is used in conditions like **myasthenia gravis** to improve muscle strength, not in organophosphate poisoning. *Flumazenil* - **Flumazenil** is an **antagonist of benzodiazepine receptors** and is used to reverse benzodiazepine overdose. - It has no role in treating organophosphate poisoning or cholinergic symptoms. *Physostigmine* - **Physostigmine** is also an **acetylcholinesterase inhibitor** that can cross the blood-brain barrier. - While it has some ophthalmic uses, it would exacerbate the cholinergic symptoms of organophosphate poisoning due to increased acetylcholine.
Question 7: A 68-year-old with depression and chronic pain is on amitriptyline. What side effect may arise if given oxybutynin for overactive bladder?
- A. Severe dry mouth (Correct Answer)
- B. Bradycardia
- C. Increased sweating
- D. Urinary incontinence
Explanation: ***Severe dry mouth*** - Both **amitriptyline** (a tricyclic antidepressant) and **oxybutynin** (an anticholinergic for overactive bladder) have significant anticholinergic effects. - The combination of these two drugs can lead to an additive effect, causing pronounced anticholinergic side effects such as **severe dry mouth**, blurred vision, constipation, and cognitive impairment. *Bradycardia* - **Anticholinergic drugs** typically cause **tachycardia** (increased heart rate) by blocking the parasympathetic nervous system's muscarinic receptors on the heart, rather than bradycardia. - While amitriptyline can affect cardiac conduction, severe bradycardia is not a typical **additive anticholinergic side effect** in this context. *Increased sweating* - **Anticholinergic drugs** like amitriptyline and oxybutynin inhibit the activity of sweat glands, which are primarily innervated by cholinergic nerves. - Therefore, the combination of these drugs would likely lead to **decreased sweating** (anhidrosis) rather than increased sweating. *Urinary incontinence* - **Oxybutynin** is prescribed specifically to treat **overactive bladder** and reduce urinary incontinence by relaxing the detrusor muscle. - Therefore, it would improve rather than worsen urinary incontinence; however, it can cause **urinary retention** due to its anticholinergic effect, especially in older male patients.
Question 8: Mechanism of action of d-tubocurarine is:
- A. Competitive, nondepolarizing block at the Nm cholinergic receptor (Correct Answer)
- B. Noncompetitive, depolarizing block at the Nm cholinergic receptor
- C. Non-competitive, nondepolarizing block at the Nm cholinergic receptor
- D. Competitive, depolarizing block at the Nm cholinergic receptor
Explanation: ***Competitive, nondepolarizing block at the Nm cholinergic receptor*** - **d-tubocurarine** acts as a **competitive antagonist** at the **nicotinic muscle (Nm) cholinergic receptors** on the motor endplate. - It competes with **acetylcholine (ACh)** for binding sites, preventing ACh from activating the receptor and causing **muscle paralysis** without depolarization. *Noncompetitive, depolarizing block at the Nm cholinergic receptor* - This describes the mechanism of action of **depolarizing neuromuscular blockers** like **succinylcholine**, which first *depolarize* the motor endplate before causing paralysis. - d-tubocurarine does not cause initial depolarization; it directly blocks the receptor. *Non-competitive, nondepolarizing block at the Nm cholinergic receptor* - While d-tubocurarine is **nondepolarizing**, it is a **competitive antagonist**, not a non-competitive one. - A non-competitive block would involve binding to a different site on the receptor or an associated ion channel, altering receptor function indirectly. *Competitive, depolarizing block at the Nm cholinergic receptor* - This option incorrectly combines the concepts, as **depolarizing blockers** like succinylcholine act initially by **depolarizing** the endplate, whereas d-tubocurarine is purely a **nondepolarizing** agent. - The "competitive" aspect would be true for the binding of ACh to its site on a depolarizing agent, but the effect of d-tubocurarine is simply to block, not depolarize.
Question 9: Mechanism of action of curare-like drugs?
- A. Blocks ACh receptors (Correct Answer)
- B. Agonistic with ACh receptors
- C. Inhibits ACh synthesis
- D. Causes persistent depolarization
Explanation: ***Blocks ACh receptors*** - Curare-like drugs are **competitive antagonists** at the **nicotinic acetylcholine receptors (nAChRs)** found at the neuromuscular junction. - By binding to these receptors, they prevent acetylcholine (ACh) from binding and activating the receptors, thereby **inhibiting muscle contraction**. *Inhibits ACh synthesis* - Drugs that inhibit ACh synthesis typically target enzymes like **choline acetyltransferase**. - This mechanism would reduce the amount of ACh available, but curare acts directly at the *receptor level*. *Causes persistent depolarization* - This is the mechanism of action of **depolarizing neuromuscular blockers** like succinylcholine. - They initially activate the receptor, causing a brief depolarization, followed by a sustained depolarization that renders the muscle unresponsive. *Agonistic with ACh receptors* - An agonist binds to and activates a receptor, mimicking the effect of the natural ligand (acetylcholine in this case). - Curare-like drugs are **antagonists**; they bind to the receptor but do not activate it, instead blocking ACh binding.
Question 10: A patient with diabetes and COPD developed postoperative urinary retention. Which of the following drugs can be used for short term treatment to relieve the symptoms of this person?
- A. Bethanechol (Correct Answer)
- B. Methacholine
- C. Terazosin
- D. Tamsulosin
Explanation: ***Bethanechol*** - This **muscarinic agonist** increases detrusor muscle tone and bladder contraction, which helps to facilitate urination and relieve **postoperative urinary retention**. - It has a relatively selective action on the bladder with fewer serious systemic side effects compared to other cholinergic agonists, making it suitable for this scenario. - While bethanechol can potentially cause mild bronchoconstriction, its effects are **much less pronounced than methacholine**, and it remains the **standard treatment** for postoperative urinary retention even in patients with COPD when used cautiously and for short-term management. *Methacholine* - While also a **muscarinic agonist**, methacholine has a less selective action than bethanechol and more pronounced **cardiovascular and respiratory effects**. - It causes significant **bronchoconstriction** and is **contraindicated in COPD patients**. - Its primary clinical use is in the diagnosis of **bronchial hyperreactivity** (methacholine challenge test) and not for urinary retention. *Terazosin* - This is an **alpha-1 adrenergic antagonist** used to treat **benign prostatic hyperplasia (BPH)** and hypertension. - It works by relaxing smooth muscle in the prostate and bladder neck, which can improve urine flow in obstructive conditions but would **not stimulate bladder contraction** needed in **postoperative urinary retention** (which is a hypotonic/atonic bladder problem). *Tamsulosin* - Similar to terazosin, tamsulosin is a **selective alpha-1a adrenergic antagonist** primarily used for BPH. - While it relaxes smooth muscle in the prostate to improve urine flow in obstructive conditions, it does **not directly stimulate bladder muscle contraction** and, therefore, is not appropriate for initiating urination in **postoperative urinary retention**.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free